Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease
dc.contributor.author | Eslam, M | |
dc.contributor.author | Hashem, AM | |
dc.contributor.author | Leung, R | |
dc.contributor.author | Romero-Gomez, M | |
dc.contributor.author | Berg, T | |
dc.contributor.author | Dore, GJ | |
dc.contributor.author | Chan, HLK | |
dc.contributor.author | Irving, WL | |
dc.contributor.author | Sheridan, David | |
dc.contributor.author | Abate, ML | |
dc.contributor.author | Adams, LA | |
dc.contributor.author | Mangia, A | |
dc.contributor.author | Weltman, M | |
dc.contributor.author | Bugianesi, E | |
dc.contributor.author | Spengler, U | |
dc.contributor.author | Shaker, O | |
dc.contributor.author | Fischer, J | |
dc.contributor.author | Mollison, L | |
dc.contributor.author | Cheng, W | |
dc.contributor.author | Powell, E | |
dc.contributor.author | Nattermann, J | |
dc.contributor.author | Riordan, S | |
dc.contributor.author | McLeod, D | |
dc.contributor.author | Armstrong, NJ | |
dc.contributor.author | Douglas, MW | |
dc.contributor.author | Liddle, C | |
dc.contributor.author | Booth, DR | |
dc.contributor.author | George, J | |
dc.contributor.author | Ahlenstiel, G | |
dc.date.accessioned | 2016-01-26T21:44:50Z | |
dc.date.available | 2016-01-26T21:44:50Z | |
dc.date.issued | 2015-05 | |
dc.identifier.issn | 2041-1723 | |
dc.identifier.issn | 2041-1723 | |
dc.identifier.other | 6422 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/4237 | |
dc.description.abstract |
<jats:title>Abstract</jats:title><jats:p>Tissue fibrosis is a core pathologic process that contributes to mortality in ~45% of the population and is likely to be influenced by the host genetic architecture. Here we demonstrate, using liver disease as a model, that a single-nucleotide polymorphism (<jats:italic>rs12979860)</jats:italic> in the intronic region of interferon-λ4 (IFNL4) is a strong predictor of fibrosis in an aetiology-independent manner. In a cohort of 4,172 patients, including 3,129 with chronic hepatitis C (CHC), 555 with chronic hepatitis B (CHB) and 488 with non-alcoholic fatty liver disease (NAFLD), those with rs12979860CC have greater hepatic inflammation and fibrosis. In CHC, those with rs12979860CC also have greater stage-constant and stage-specific fibrosis progression rates (<jats:italic>P</jats:italic><0.0001 for all). The impact of rs12979860 genotypes on fibrosis is maximal in young females, especially those with HCV genotype 3. These findings establish rs12979860 genotype as a strong aetiology-independent predictor of tissue inflammation and fibrosis.</jats:p> | |
dc.format.extent | 0-0 | |
dc.format.medium | Electronic | |
dc.language | en | |
dc.language.iso | en | |
dc.publisher | Springer Science and Business Media LLC | |
dc.subject | Cohort Studies | |
dc.subject | Female | |
dc.subject | Genotype | |
dc.subject | Hepatitis, Chronic | |
dc.subject | Humans | |
dc.subject | Interleukins | |
dc.subject | Liver | |
dc.subject | Liver Cirrhosis | |
dc.subject | Logistic Models | |
dc.subject | Non-alcoholic Fatty Liver Disease | |
dc.subject | Polymorphism, Single Nucleotide | |
dc.subject | Sex Factors | |
dc.subject | Statistics, Nonparametric | |
dc.title | Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease | |
dc.type | journal-article | |
dc.type | Journal Article | |
dc.type | Multicenter Study | |
dc.type | Research Support, Non-U.S. Gov't | |
plymouth.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000352633900006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008 | |
plymouth.issue | 0 | |
plymouth.volume | 6 | |
plymouth.publication-status | Published online | |
plymouth.journal | Nature Communications | |
dc.identifier.doi | 10.1038/ncomms7422 | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Faculty of Health/Peninsula Medical School | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
dc.publisher.place | England | |
dcterms.dateAccepted | 2015-01-28 | |
dc.identifier.eissn | 2041-1723 | |
dc.rights.embargoperiod | Not known | |
rioxxterms.versionofrecord | 10.1038/ncomms7422 | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2015-05 | |
rioxxterms.type | Journal Article/Review |